Iqvia Holdings Inc. last reported quarterly results on Oct 27, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $4.4 billion (+8.0% year over year) and diluted EPS of $2.10. It usually reports 27–36 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 4, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Feb 5, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 27–36 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 27, 2026
27 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
4,428
+8.0%
|
350
+5.7%
|
2.10
+8.8%
|
|
Jul 28, 2026
28 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
4,368
+8.7%
|
256
-3.8%
|
1.53
-0.6%
|
|
May 5, 2026
35 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
4,151
+8.4%
|
274
+10.0%
|
1.61
+15.0%
|
|
Feb 5, 2026
36 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
4,364
+10.3%
|
514
+17.6%
|
2.99
+23.8%
|
|
Oct 28, 2025
28 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
4,100
+5.2%
|
331
+16.1%
|
1.93
+24.5%
|
|
Jul 22, 2025
22 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
4,017
+5.3%
|
266
-26.7%
|
1.54
-21.8%
|
|
May 6, 2025
36 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
3,829
+2.5%
|
249
-13.5%
|
1.40
-10.3%
|
|
Feb 6, 2025
37 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
3,958
+2.3%
|
437
-6.8%
|
2.42
-4.9%
|
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- IQV (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Durham, NC
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1478242
- Former names
- Quintiles IMS Holdings, Inc. (until Nov 3, 2017); Quintiles Transnational Holdings Inc. (until Sep 22, 2016)
Other Services-Commercial Physical & Biological Research companies
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
- Maxcyte, Inc. MXCT
All 17 Services-Commercial Physical & Biological Research companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.